Hypothalamic and gonadal components of hypogonadism in boys with Prader-Labhart- Willi syndrome.

Eiholzer U, l'Allemand D, Rousson V, Schlumpf M, Gasser T, Girard J, Grüters A, Simoni M

The Journal of clinical endocrinology and metabolism13 Dec 2005Cited by 69 (Europe PMC)

PMID16352691DOI10.1210/jc.2005-0902PepBankPUB-16352691

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In peripubertal boys with Prader-Labhart-Willi syndrome, hCG increased testosterone to 11 +/- 2 nmol/liter.
In plain wordsIn boys with Prader-Labhart-Willi syndrome, hCG increased testosterone.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseTestosterone
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
500-1500 U twice weeklyAs given in this study (human).
Measurements
Testosterone
11 nmol/liter
During hCG therapy
Testosterone reported +/- uncertainty (type not specified for this result)
2 nmol/liter
During hCG therapy
Source sentences
Summary
hCG therapy increased testosterone (11 +/- 2 nmol/liter) and reduced FSH (at 16 yr, 1.1 +/- 0.9 U/liter) levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a clinical follow-up study, divided into two samples, over a duration of 1.5 and 4.5 yr.
Summary · context
hCG (500-1500 U twice weekly) was given from age 13.5 yr to the present.
Report a problemFND-1635269101
02HumanNon-randomized trialEfficacy outcome
In boys with Prader-Labhart-Willi syndrome, hCG reduced FSH to 1.1 +/- 0.9 U/liter at 16 yr.
In plain wordsIn boys with Prader-Labhart-Willi syndrome, hCG reduced FSH levels.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseFSH
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
500-1500 U twice weeklyAs given in this study (human).
Measurements
FSH
1.1 U/liter
During hCG therapy, at 16 yr
FSH reported +/- uncertainty (type not specified for this result)
0.9 U/liter
During hCG therapy, at 16 yr
FSH
9.9 U/liter
Before hCG therapy, at puberty
FSH reported +/- uncertainty (type not specified for this result)
2.6 U/liter
Before hCG therapy, at puberty
Source sentences
Summary
hCG therapy increased testosterone (11 +/- 2 nmol/liter) and reduced FSH (at 16 yr, 1.1 +/- 0.9 U/liter) levels.
Summary
Inhibin B levels were at the lowest level of the normal range and decreased significantly between infancy and puberty (at 13 yr, 72 +/- 17 pg/ml), whereas FSH secretion increased (9.9 +/- 2.6 U/liter).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a clinical follow-up study, divided into two samples, over a duration of 1.5 and 4.5 yr.
Summary · context
hCG (500-1500 U twice weekly) was given from age 13.5 yr to the present.
Report a problemFND-1635269102
03HumanNon-randomized trialEfficacy outcome
In boys with Prader-Labhart-Willi syndrome receiving hCG, testicular volume remained low at 5.6 +/- 1 ml.
In plain wordsIn boys with Prader-Labhart-Willi syndrome receiving hCG, testicular volume remained low.
Peptide
hCG (human chorionic gonadotropin)
Outcome
Not applicableTesticular volume
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
500-1500 U twice weeklyAs given in this study (human).
Measurements
Testicular volume
5.6 ml
During hCG therapy
Testicular volume reported +/- uncertainty (type not specified for this result)
1 ml
During hCG therapy
Source sentences
Summary
Testicular volume (5.6 +/- 1 ml) and inhibin B (26.5 +/- 11.9 pg/ml) remained low.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a clinical follow-up study, divided into two samples, over a duration of 1.5 and 4.5 yr.
Summary · context
hCG (500-1500 U twice weekly) was given from age 13.5 yr to the present.
Report a problemFND-1635269103
04HumanNon-randomized trialEfficacy outcome
In boys with Prader-Labhart-Willi syndrome receiving hCG, inhibin B remained low at 26.5 +/- 11.9 pg/ml.
In plain wordsIn boys with Prader-Labhart-Willi syndrome receiving hCG, inhibin B remained low.
Peptide
hCG (human chorionic gonadotropin)
Outcome
Not applicableInhibin B
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
500-1500 U twice weeklyAs given in this study (human).
Measurements
Inhibin B
26.5 pg/ml
During hCG therapy
Inhibin B reported +/- uncertainty (type not specified for this result)
11.9 pg/ml
During hCG therapy
Source sentences
Summary
Testicular volume (5.6 +/- 1 ml) and inhibin B (26.5 +/- 11.9 pg/ml) remained low.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a clinical follow-up study, divided into two samples, over a duration of 1.5 and 4.5 yr.
Summary · context
hCG (500-1500 U twice weekly) was given from age 13.5 yr to the present.
Report a problemFND-1635269104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.